RightFit
Not yet recruitingPhase not listed

Relationship Between Insulin Dose and Complications in Type 1 Diabetes

Insulin Dose and Vascular Complications in Type 1 Diabetes: Its Role Beyond Insulin Resistance and Glycemia

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
No age limits stated
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

  • Time periods mentioned: 37 years

Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.

Show the study's own words
  • "Study Aim 1 will use existing data from the prospective Pittsburgh Epidemiology of Diabetes Complications (EDC) study cohort, comprising 658 study participants who were diagnosed with type 1 diabetes in childhood (\<17 years old) and followed for health outcomes and clinical measures for up to 37 years beginning in 1986."
Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

The goal of this observational study is to better understand how the amount of insulin people with type 1 diabetes are using relates to blood glucose control and the risk of complications. The main questions this study aims to answer are: 1) Is insulin dose related to the long-term risk of developing heart disease, kidney disease and other complications in people with type 1 diabetes, after accounting for blood glucose? and 2) Does insulin dose relate to early signs of heart and kidney disease (i.e., disease that is not clinically detectable) in people with type 1 diabetes who are using modern diabetes management regimens?

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Official eligibility criteria

Inclusion Criteria: * Study Aim 1 - All existing participants of the Pittsburgh EDC study * Study Aim 2 - Existing participants of the Pittsburgh EDC study who were alive and not withdrawn as of the most recent (2023-24) survey follow-up Exclusion Criteria: * Study Aim 1 - For each outcome of interest, individuals who already had the outcome at study baseline. * Study Aim 2 - History of major cardiovascular disease, kidney failure, or pancreatic transplant

Study sites (1)

PA